Story
Johnson & Johnson Shares Rise on Report of $20 Billion Orthopedics Unit Sale Talks
Johnson & Johnson (NYSE: JNJ) shares climbed in pre-market trading, outperforming a declining broader market, following reports that private equity firm Apollo Global Management is in talks to acquire its orthopedics division for nearly $20 billion.
Details of the Potential Divestiture
Shares of J&J rose 1.4% in pre-open trading Monday after reports surfaced late Friday that Apollo is in active discussions to purchase the DePuy Synthes orthopedics business. The news, initially reported by Bloomberg and subsequently confirmed by The Wall Street Journal, suggests a significant acceleration of J&J's plans to separate the unit.
Investors appear to view a direct sale as a more efficient and value-accretive path than the standalone spinoff J&J had announced in October 2025. A deal would allow the company to quickly unlock capital and streamline its focus on higher-growth segments.
Strategic Rationale and Market Context
A sale of DePuy Synthes would align with J&J's strategy to concentrate on its higher-margin Innovative Medicine and core MedTech businesses. At the recent Wells Fargo Healthcare Conference, MedTech chairman Tim Schmid reiterated the company's commitment to finding the path for the separation—whether a sale or a public spin—that creates the most shareholder value.
AdThe stock's advance is particularly notable given the negative market sentiment on Monday morning. J&J's gain came as S&P 500 futures slipped 0.7% and the Dow Jones Industrial Average fell 0.4%, underscoring that the move was driven by company-specific news rather than a broader market tailwind.
Supporting Catalysts
Beyond the potential deal, other factors are supporting investor sentiment. J&J management is presenting today at the Morgan Stanley 24th Annual Global Healthcare Conference, providing direct engagement with institutional investors.
Furthermore, the company recently published positive Phase 3 PAPILLON data for its lung cancer treatment, Rybrevant. The study highlighted the strength of J&J's oncology pipeline, showing a median overall survival of 34.3 months for patients treated with Rybrevant versus 27.9 months for chemotherapy alone.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.